• 1
    Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. New Engl J Med. 2005;353:1784-1792.
  • 2
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
  • 3
    Rosner GL, Hargis JB, Hollis DR, et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol. 1996;14:3000-3008.
  • 4
    Gorin SS, Heck JE, Cheng B, Smith SJ. Delays in breast cancer diagnosis and treatment by racial/ethnic group. Arch Intern Med. 2006;166:2244-2252.
  • 5
    Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165:1267-1273.
  • 6
    Colleoni M, Li S, Gelber RD, et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet. 2005;366:1108-1110.
  • 7
    van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152:514-527.
  • 8
    Carmichael AR, Bates T. Obesity and breast cancer: a review of the literature. Breast. 2004;13:85-892.
  • 9
    Vona-Davis L, Rose DP. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt). 2009;18:883-893.
  • 10
    Clarke LD, Plevritis SK, Boer R, Cronin KA, Feuer EJ. A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends. J Natl Cancer Inst Monogr. 2006;36:96-105.
  • 11
    Tan SY, van Oortmarssen GJ, de Koning HJ, Boer R, Habbema JD. The MISCAN-Fadia continuous tumor growth model for breast cancer. J Natl Cancer Inst Monogr. 2006;36:56-65.
  • 12
    Mandelblatt J, Schechter CB, Lawrence W, Yi B, Cullen J. The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000. J Natl Cancer Inst Monogr. 2006;36:47-55.
  • 13
    Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151:738-747.
  • 14
    van Ravesteyn NT, Schechter CB, Near AM, et al. Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States. Epidemiol Biomarkers Prev. 2011;20:112-122.
  • 15
    Chang Y, Schechter CB, van Ravesteyn NT, et al. Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortality. Breast Cancer Res Treat. 2012;136:823-835.
  • 16
    American Cancer Society. Cancer Prevention & Early Detection Facts & Figures 2012. Atlanta: American Cancer Society, Inc. Accessed October 2012.
  • 17
    CISNET Cancer Intervention and Surveillance Modeling Network. Accessed May 2012.
  • 18
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology v.2.2008. Accessed September 2009.
  • 19
    Carter SB, Gartner SS, Haines MR, et al. Historical Statistics of the United States, Volume One: Population. New York: Cambridge University Press, 2006.
  • 20
    Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, CDC. http://www/cdc/gov/nchs/nhanes.htm. Accessed May 2012.
  • 21
    Wang YC, Graubard BI, Rosenberg MA, et al. Derivation of background mortality by smoking and obesity in cancer stimulation models. Med Decis Making. 2013;33:176-197.
  • 22
    Wang YC, Colditz GA, Kuntz KM. Forecasting the obesity epidemic in the aging U.S. population. Obesity. 2007;15:2855-2865.
  • 23
    Wang Y, Beydoun MA. The obesity epidemic in the United States--gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev. 2007;29:6-28.
  • 24
    Flegal K, Carroll M, Ogden C, Johnson C. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307:491-497.
  • 25
    Holford TR, Cronin KA, Mariotto AB, Feuer EJ. Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr. 2006;19-25.
  • 26
    Cronin KA, Mariotto AB, Clarke LD, Feuer EJ. Additional common inputs for analyzing impact of adjuvant therapy and mammography on U.S. mortality. J Natl Cancer Inst Monogr. 2006;26-29.
  • 27
    Cronin KA, Yu B, Krapcho M, et al. Modeling the dissemination of mammography in the United States. Cancer Causes Control. 2005;16:701-712.
  • 28
    Zhu K, Wu H, Jatoi I, Potter J, Shriver C. Body mass index and use of mammography screening in the United States. Prev Med. 2006;381-385.
  • 29
    Breast Cancer Surveillance Consortium. Performance Measures for 3,884,059 Screening Mammography Examinations from 1996 to 2007 by Age— based on BCSC data as of 2008. Accessed April 2008.
  • 30
    Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD. Accessed January 2012.
  • 31
    Cui Y, Whiteman M, Flaws J, et al. Body mass and stage of breast cancer at diagnosis. Int J Cancer. 2002;98:279-283.
  • 32
    Hahn KM, Bondy ML, Selvan M, et al. Factors associated with advanced disease stage at diagnosis in a population-based study of patients with newly diagnosed breast cancer. Am J Epidemiol. 2007;166:1035-1044.
  • 33
    Bekele BN, Nieto-Barajas LE, Munsell MF. Analysis of partially incomplete tables of breast cancer patients' characteristics with an ordinal variable. J Stat Theory Pract. 2012 [in press].
  • 34
    Suzuki R, Orsini N, Saji S, Key TJ, Wolk A. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status—a meta-analysis. Int J Cancer. 2009;124:698-712.
  • 35
    Mariotto AB, Feuer EJ, Harlan LC, Abrams J. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. J Natl Cancer Inst Monogr. 2006;7-15.
  • 36
    Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst 2002;94:1626-1634.
  • 37
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717.
  • 38
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930-942.
  • 39
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
  • 40
    Clarke M, Coates AS, Darby SC, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008;371:29-40.
  • 41
    National Center for Health Statistics. United States, 2000. Hyattsville, Maryland: Public Health Service 2000. Accessed May 2012.
  • 42
    Human Mortality Database, Centers for Disease Control and Prevention, Publications and Information Products, Life Tables 2011. Accessed May 2012.
  • 43
    Rosenberg MA. Competing risks to breast cancer mortality. J Natl Cancer Inst Monogr. 2006;15-19.
  • 44
    Projected population by single year of age, sex, race, and hispanic origin for the United States: July 1, 2000 to July 1, 2050. Accessed May 2012.
  • 45
    Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126:529-537.
  • 46
    Wigertz A, Ahlgren J, Holmqvist M, et al. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat. 2012;133:367-73.
  • 47
    Trivedi AN, Rakowski W, Ayanian JZ. Effect of cost sharing on screening mammography in Medicare health plans. New Engl J Med. 2008;358:375-383.
  • 48
    Vernon SW, McQueen A, Tiro JA, del Junco DJ. Interventions to promote repeat breast cancer screening with mammography: a systematic review and meta-analysis. J Natl Cancer Inst. 2010;102:1023-1039.
  • 49
    Bleyer A, Welch HG. Effect of three decades of screening mammogrpahy on breast cancer incidence. New Engl J Med. 2012;367:1998-2005.
  • 50
    de Gelder R, Heijnsdijk EA, van Ravesteyn NT, Fracheboud J, Draisma G, de Koning HJ. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev. 2011;33:111-121.
  • 51
    Mandelblatt JS, Stout N, Trentham-Dietz A. To screen or not to screen women in their 40s for breast cancer: is personalized risk-based screening the answer? Ann Internal Med. 2011;155:58-60.
  • 52
    Elmore JG, Reisch LM, Barton MB, et al. Efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst. 2005;97:1035-1043.
  • 53
    Goodwin P. Energy balance and cancer prognosis. In: McTiernan A. Mechanisms Associating Physical Activity With Cancer Incidence: Exercise and Immune Function. Boca Raton, FL: Taylor & Francis Group, LLC; 2006:405-436.
  • 54
    Bonomi AE, Boudreau DM, Fishman PA, et al. Quality of life valuations of mammography screening. Qual Life Res. 2008;17:801-814.